2024 年 7 月 12 日 公司研究 蛋氨酸业务增长强劲,Q2 业绩大幅增长 ——安迪苏(600299.SH)2024 年半年度业绩预增公告点评 买入(维持) 当前价:10.15 元 作者 分析师:赵乃迪 执业证书编号:S0930517050005 010-57378026 zhaond@ebscn.com 分析师:蔡嘉豪 | | | |---------------------|----------------| | 执业证书编号: | S0930523070003 | | 021-52523800 | | | caijiahao@ebscn.com | | | 市场数据 | | | 总股本(亿股) | 26.82 | | 总市值(亿元): | 272.21 | | 一年最低/最高(元): | 6.45/10.44 | | 近 3 月换手率: | 20.86% | 股价相对走势 -18% -6% 5% 17% 28% 07/23 10/23 01/24 04/24 安迪苏 沪深300 收益表现 | | | | | |------|------|-------|-------| | % | 1M | 3M ...

证券代码：600299 证券简称：安迪苏 公告编号：2024-028 蓝星安迪苏股份有限公司 2024 年半年度业绩预增公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本期业绩预告适用于实现盈利，且净利润与上年同期相比上升 50%以上。 蓝星安迪苏股份有限公司（以下简称"公司"）预计 2024 年上半年实现归属于 上市公司股东的净利润为 55,000 万元到 65,000 万元，与上年同期相比，预计 增加 51,660 万元到 61,660 万元，同比增加 1546.71%到 1846.11%。 预计 2024 年上半年归属于上市公司股东的扣除非经常性损益的净利润为 65,000 万元到 75,000 万元，与上年同期相比，预计增加 63,936 万元到 73,936 万元，同比增加 6009.02%到 6948.87%。 一、本期业绩预告情况 (一) 业绩预告期间 2024 年 1 月 1 日至 2024 年 6 月 30 日 (二) 业绩预告情况 经公司初步测算，预计 2024 年半年度实现归属于上市 ...

Hello, everyone. I'm Hao Zhigang, Chairman and CEO of IDU CEO. Welcome to the presentation of IDU CEO's Q1 2024 results. Frederic Jacquin, our Group CEO, and Vidinia Kach, our Group CFO, are with me today to walk you through our business highlights, financial metrics, and the 2024 outlook. Thank you, Dr. Hao, and hello, everyone. Before the presentation of our Q1 2024 results, please have a look at our disclaimer. Thank you. The starting of this year is showing encouraging signs of rebound. In Q1 2024, we d ...

蓝星安迪苏股份有限公司 蓝星安迪苏股份有限公司 2024 年一季报投资者沟通会议记录 一、会议时间 2024 年 5 月 6 日-2024 年 5 月 10 日 二、参与单位名称及人员姓名 部分参会机构名单详见附件清单。 重要提示：参会机构名单由组织机构提供并经整理后展示。公司无法保证 参会机构单位名称的完整性、准确性，敬请投资者注意。 三、公司接待人员 董事长兼总经理（CEO）：郝志刚先生 首席运营官兼副总经理：Frederic Jacquin 先生 首席财务官：Virginie Cayatte 女士 董事会秘书：蔡昀女士 四、会议地点 Teams 线上会议。 五、 主要内容 投资者交流会以线上交流互动形式召开，公司高管团队围绕经营成果、 业务发展和未来展望等方面，向投资者介绍了公司 2024 年一季度业绩情况， 并在信息披露允许的范围内就投资者普遍关注的问题进行回答。公司与投 资者主要沟通内容如下： 1 蓝星安迪苏股份有限公司 1. 公司蛋氨酸业务的成本与同行的比较，我们自身欧洲和国内工厂的比较？ 从液体蛋氨酸产品来说，目前我们在中国和欧洲拥有两个液体蛋氨酸生产 平台，它们使用相同的生产工艺，通过内部对标 ...

2024年04月14日 公 司点评 公 增持 / 维持 司 安迪苏(600299) 研 究 业绩逐步改善，产能扩充助力成长 ◼ 走势比较 事件：公司发布 2023 年年报，2023 年公司实现营收 131.84 亿 元，同比-9.26%；归母净利润0.52亿元，同比-95.82%。 10% 太 2% 三季度以来市场需求复苏，业绩逐步改善。2023年，由于经济疲 平 洋 (6%)41/4/32 52/6/32 5/9/32 61/11/32 72/1/42 8/4/42 软 受、 销地 售缘 价政 格治 下及 降欧 和洲 原能 材源 料危 成机 本等 上宏 升观 双环 重境 影影 响响 ，， 公全 司球 2需 02求 3 增 年长 全放 年缓 业。 绩 (14%) 证 承压。2023 年公司销售毛利率为 21.38%，同比下降 6.13pcts。但自 (22%) 券 2023年第三季度以来，市场需求正在缓慢复苏，由于产量增长、价格 (30%) 稳定、原材料和能源成本降低，公司业绩正在改善。公司2023年第四 股 安迪苏 沪深300 季度归母净利润为0.87亿元，环比大幅改善。 份 有 ◼ 股票数据 公司产品组合 ...

证券研究报告 | 公司动态点评 2024 年 04月 07日 安迪苏（600299.SH） 下半年业绩逐渐改善，国内外产能布局强化竞争优势 财务指标 2022A 2023A 2024E 2025E 2026E 买入（维持评级） 营业收入（百万元） 14,529 13,184 13,789 14,831 16,284 股票信息 增长率yoy（%） 12.9 -9.3 4.6 7.6 9.8 归母净利润（百万元） 1,247 52 383 801 1,093 行业 基础化工 增长率yoy（%） -15.3 -95.8 633.8 109.3 36.4 2024年4月3日收盘价（元） 9.11 ROE（%） 8.4 0.3 2.6 5.2 6.7 总市值（百万元） 24,432.12 EPS最新摊薄（元） 0.46 0.02 0.14 0.30 0.41 流通市值（百万元） 24,432.12 P/E（倍） 18.6 443.7 60.5 28.9 21.2 总股本（百万股） 2,681.90 P/B（倍） 1.5 1.5 1.5 1.5 1.4 流通股本（百万股） 2,681.90 资料来源：公司财报，长城证券产 ...

公 司 研 究 安迪苏（600299.SH）：业绩短期承 2024年3月29日 强烈推荐/维持 压，产能持续扩张巩固龙头地位 东 安迪苏 公司报告 兴 证 券 安迪苏发布2023年年报：全年实现营业收入为131.84亿元，YoY-9.26%，归 公司简介： 股 母净利润为0.52亿元，YoY-95.82%，EPS为0.02元。公司拟每10股派发现 安迪苏于 2006 年被中国蓝星集团收购，于 份 金红利0.6元（含税）。 2015 年借壳蓝星集团旗下的蓝星新材在 A 有 股上市。公司是全球第二大蛋氨酸生产商， 限 受到产品销售价格下滑，以及原材料、能源成本上升的双重挤压，公司业绩下 可同时提供固体蛋氨酸和液体蛋氨酸，是动 公 滑。从收入端看，2023年公司主要产品蛋氨酸市场均价同比2022年有所下滑， 物营养与健康行业的全球领军企业。 资料来源：公司公告、东兴证券研究所 司 导致公司营收小幅下滑。从利润端看，公司毛利率受到产品价格下滑的影响同 交易数据 比下滑7个百分点至21%，同时也受到资产减值和相关重组成本的影响（其中 证 券 主要由于 Commentry 固体蛋氨酸生产线，Innov’ia 的老旧工厂以 ...

Financial Performance - Net profit attributable to shareholders of the parent company for 2023 was RMB 52,165,518[4] - Cumulative distributable profit of the parent company as of December 31, 2023, was RMB 489,335,867[4] - Revenue in 2023 decreased by 9.26% year-on-year to RMB 13.18 billion, compared to RMB 14.53 billion in 2022[21] - Net profit attributable to shareholders dropped significantly by 95.82% to RMB 52.17 million in 2023, down from RMB 1.25 billion in 2022[21] - Basic earnings per share (EPS) fell by 95.65% to RMB 0.02 in 2023, compared to RMB 0.46 in 2022[22] - The weighted average return on equity (ROE) decreased by 8.36 percentage points to 0.35% in 2023[22] - Revenue for the period decreased by 9.26% to RMB 13,183,748,624 compared to the same period last year[54] - Gross profit margin for the nutrition and health industry decreased by 7 percentage points to 21%[56] - Functional products revenue decreased by 15% to RMB 8,807,341,566, with a gross margin reduction of 11 percentage points[56] - Special products revenue increased by 8% to RMB 3,593,810,639, but gross margin decreased by 4 percentage points[56] - Revenue in China increased by 11% to RMB 1,793,361,133, while other regions experienced declines[56] - Sales expenses increased by 5.49% to RMB 1,227,058,560, and management expenses rose by 9.84% to RMB 768,915,157[62] - R&D expenses increased by 18.17% to RMB 419,245,587, reflecting higher investment in innovation[54] - Net cash flow from operating activities increased significantly by 59.89% to RMB 2,764,212,304[54] - Total R&D investment in 2023 was RMB 518,242,447, accounting for 3.93% of total revenue, with 8.20% of R&D investment capitalized[63] - Operating cash flow in 2023 was RMB 2,764,212,304, a significant increase from RMB 1,728,821,216 in 2022, primarily due to strict cash and working capital management[67] - Total R&D expenditure in 2023 was RMB 518,242,447, accounting for 3.4% of net assets and 3.9% of operating revenue[84] - The total actual compensation paid to directors, supervisors, and senior management during the reporting period was RMB 52.44 million[153] - The company allocated a cash dividend of 404,967,092.22 yuan for 2022, representing 32.48% of the net profit attributable to shareholders[180] Profit Distribution and Dividends - Proposed cash dividend of RMB 0.6 per 10 shares, totaling RMB 160,914,076 (tax inclusive)[4] - The company plans to maintain the per-share distribution ratio and adjust the total distribution amount if the total share capital changes before the equity distribution record date[4] - The profit distribution plan is subject to approval at the 2023 Annual General Meeting of Shareholders[4] - The company's cash dividend policy mandates that at least 30% of the distributable profits be allocated as cash dividends when the company is profitable and has positive undistributed profits[180] Cash Flow and Working Capital Management - Operating cash flow increased by 59.89% to RMB 2.76 billion in 2023, driven by strict cash and working capital management[22] - Net cash flow from operating activities increased significantly by 59.89% to RMB 2,764,212,304[54] - Operating cash flow in 2023 was RMB 2,764,212,304, a significant increase from RMB 1,728,821,216 in 2022, primarily due to strict cash and working capital management[67] Non-Recurring Gains and Losses - Non-recurring gains and losses amounted to RMB 39.17 million in 2023, primarily due to government subsidies and asset disposal losses[25][26] Asset and Liability Management - Total assets increased slightly by 0.80% to RMB 21.51 billion at the end of 2023[21] - The company's net debt level decreased due to improved cash flow management[22] - Derivative financial assets increased by RMB 11.39 million, from RMB 4.88 million to RMB 16.28 million, impacting current profits by RMB 12.74 million[27] - Derivative financial liabilities decreased by RMB 354,904, from RMB 363,722 to RMB 8,818, impacting current profits by RMB -414,944[27] - Other equity instrument investments increased by RMB 15.15 million, from RMB 262.66 million to RMB 277.80 million[27] - Other non-current financial assets increased by RMB 33.15 million, from RMB 75.87 million to RMB 109.02 million, impacting current profits by RMB 27.84 million[27] - Total fair value changes amounted to RMB 60.05 million, with a total impact on current profits of RMB 40.16 million[27] - Overseas assets accounted for 55% of total assets, amounting to RMB 11,738,245,328, reflecting the company's global presence in animal nutrition additives[69] Environmental and Sustainability Goals - The company aims to reduce greenhouse gas emissions by 37% from 2020 to 2035 while maintaining business growth[30] - The company has already achieved its 2025 target of reducing greenhouse gas emissions, energy consumption, and water usage by 20% compared to 2025 levels[30] - The company has established a carbon reduction roadmap for 2050 in collaboration with a leading French sustainability consulting firm[30] - The company is committed to aligning its environmental goals with the Paris Agreement and the United Nations Framework Convention on Climate Change[30] - The company focuses on four key areas: reducing its own carbon footprint, contributing to reducing the carbon footprint across the value chain, ensuring responsible behavior towards employees and stakeholders, and enhancing governance and sustainability communication[30] - The company invested 23.38 million yuan in environmental protection during the reporting period[190] - The company's subsidiary, BlueStar Adisseo Nanjing Co., Ltd., maintained stable and compliant emissions of waste gas, wastewater, and noise in 2023[191] - The company's annual emissions of sulfur dioxide (SO2) were 3.65 tons, with an emission concentration of 1.148 mg/m³, well below the permitted limit of 200 mg/m³[192] - Nitrogen oxides (NOx) emissions totaled 134.47 tons annually, with an emission concentration of 53.04 mg/m³, within the permitted limits of 200-300 mg/m³[192] - Non-methane total hydrocarbon (NMHC) emissions were 4.149 tons annually, with an emission concentration of 1.25 mg/m³, significantly below the permitted limit of 80 mg/m³[193] - Chemical oxygen demand (COD) in wastewater was 44.11 tons annually, with a concentration of 122 mg/L, well below the permitted limit of 500 mg/L[194] - Ammonia nitrogen (NH3-N) in wastewater was 2.07 tons annually, with a concentration of 6.2 mg/L, significantly below the permitted limit of 45 mg/L[195] - Total suspended solids (SS) in wastewater were 10.96 tons annually, with a concentration of 31 mg/L, well below the permitted limit of 400 mg/L[195] - Five-day biochemical oxygen demand (BOD5) in wastewater was 12.84 tons annually, with a concentration of 36 mg/L, significantly below the permitted limit of 300 mg/L[195] - Total nitrogen (TN) in wastewater was 4.21 tons annually, with a concentration of 11.68 mg/L, well below the permitted limit of 70 mg/L[195] - Noise levels at the factory boundary were 59.98 dB(A) during the day and 52.29 dB(A) at night, both below the permitted limits of 65 dB(A) and 55 dB(A) respectively[195] - Hazardous waste generation in 2023 was 91,405.67 tons, with 91,002.95 tons processed internally and 402.73 tons transferred out[196] - The company completed the environmental online monitoring system for elevated flares in 2023 and connected it to the environmental protection department's platform[198] - The Nanjing factory's waste heat power generation project entered the testing phase in January 2024, aiming to utilize excess steam more effectively[198] - The acrylic acid wastewater treatment and reclaimed water reuse project is expected to start construction in 2024 and be operational by 2025, significantly reducing nitrogen oxide emissions and natural gas consumption[198] - The Nanjing factory passed the second round of clean production audit in February 2023, achieving the first level (international advanced level) of clean production[199] - The environmental protection acceptance of the Nanjing factory's second-phase project was completed on June 30, 2023[199] - The company completed two full-scale emergency drills for environmental incidents in 2023 and plans to continue drills in 2024 to enhance response capabilities[200] Production and Capacity Expansion - The company successfully increased annual production capacity by 80,000 tons through the expansion of European production platforms, including new production lines at Burgos and Les Roches factories[33] - The Nanjing liquid methionine plant (BANC2) reached a total capacity of 350,000 tons, making it one of the largest and most cost-competitive liquid methionine production platforms globally[33] - A new solid methionine plant with an annual capacity of 150,000 tons is planned in Quanzhou, expected to be operational by 2027[33] - The European production platform has successfully added 80,000 tons/year of liquid methionine capacity since Q3 2021, enhancing market competitiveness[36] - The Nanjing production platform's Phase II plant, with an annual capacity of 180,000 tons of liquid methionine, was completed and operational in September 2022[37] - A new solid methionine plant in Quanzhou, with an annual capacity of 150,000 tons, is planned to start production in 2027[37] - The company's market share of methionine increased from 24% to 27% between 2012 and 2017, maintaining a strong position in recent years[37] - The company decided not to restart the solid methionine production plant in Commentry in January 2024 to improve cost competitiveness[37] - The company holds approximately 20% of the global feed-grade Vitamin A production capacity[38] - Vitamin A prices dropped sharply from April 2022 due to a major producer's return to the market[38] - The company reduced Vitamin A production from Q4 2022 to optimize working capital management amid weak demand[38] - The company's global finished product transportation volume increased to 1.318 million tons in 2023, up from 1.098 million tons in 2022[80] - Anhui transported 103,000 tons of intermediate products using dedicated railway tank cars in 2023 for safety reasons[80] - The company's product portfolio includes methionine, vitamins, enzyme preparations, and other specialty products for animal feed applications[82] - The company's raw materials and finished products are stored in tanks and traditional warehouses, with unified management standards for both in-plant and off-plant warehouses[81] - The company's transportation strategy prioritizes safety, pollution reduction, and cost efficiency, with some routes adopting multimodal transportation to reduce carbon emissions[80] - The company's global market access planning enables precise technical specifications for each market, facilitating international business opportunities[82] - The company successfully obtained market access for its products in over 120 countries despite strict global trade measures and complex regulatory environments[83] - A new solid methionine plant in Quanzhou with a designed capacity of 150,000 tons/year is under construction, with an investment of RMB 170 million and expected completion in 2027[86][87] - The Nanjing plant's total capacity has been expanded to 350,000 tons/year after the completion of debottlenecking and liquid methionine phase II projects[88] - The company permanently closed the Commentry solid methionine production line in January 2024 to improve cost competitiveness[89] - Procurement costs for key raw materials decreased significantly: propylene (-17%), methanol (-14%), and sulfur (-43%)[90] - Energy procurement costs also decreased: natural gas (-33%) and electricity (-29%)[91] - The company uses derivative financial instruments to manage currency exchange rate risks, primarily through cash flow hedging[95][96] - Direct sales through the company's own network account for over 85% of total sales, with the remainder through distributors[94] Product Development and Innovation - A new product, DynOmik™, was launched in the US market in Q3 2023, aimed at improving milk production efficiency and sustainability[33] - The company's specialty products business achieved continuous revenue growth, driven by growth in aquatic and monogastric products, despite weak demand in the US and China dairy markets[33] - The company's joint venture, Kaidi Su, entered trial production and signed a strategic cooperation agreement with a leading Chinese feed producer for its innovative single-cell protein product[33] - The company launched a new technical service, Nestor, in Q3 2022, which has been widely adopted by key clients for feed formulation optimization[34] - DynOmik™, a new ruminant additive product, was fully launched in the North American market after its initial release in two US states in Q3 2023[34] - The company's R&D efforts are focused on five pillars: green production, new testing, multi-dimensional impact, innovation synergy, and digital empowerment[33] - The company's new R&D center in Lyon, operational in Q4 2023, integrates chemical, engineering, nutritional, and analytical capabilities[34] - The company launched DynOmik™ in the US in 2023, the first solution to increase milk production while reducing methane emissions in cows[51] - Adisseo's Rovabio Phyplus, the latest generation of phytase, improves overall nutritional efficiency, sustainability, and feed digestibility[51] - Adisseo established the "Sinochem Animal Nutrition Center Research Institute" in early 2023, strengthening collaborations with international labs, universities, and research institutions[50] - Adisseo's innovation lab focuses on disruptive technologies, products, and services to enhance customer productivity, sustainability, and animal health[46] - Adisseo's dual-pillar strategy includes maintaining leadership in the methionine market and accelerating the development of specialty product business[47] - The company's R&D investment in 2023 increased significantly compared to 2022, driven by increased project investments, with strategic collaborations established with universities and research institutions in Europe, China, and Singapore[66] - The company has 4 R&D centers and 2 experimental stations globally, focusing on areas such as biotechnology, chemical processes, and smart agriculture[84] - The company's long-term performance evaluation standards focus on sustainable shareholder value creation, including total shareholder return and profitability growth[176] - The company emphasizes the relationship between individual and organizational performance in determining executive compensation[177] Market and Competitive Position - The company's performance improved in the second half of 2023, with Q4 revenue reaching RMB 3.57 billion, the highest among all quarters[24] - Asset impairments and restructuring costs, particularly related to the closure of the Commentry solid methionine production line and Innov'ia plant, significantly impacted profitability[22] - The company's liquid methionine technology and cost leadership position it as one of the lowest-cost producers globally, with significant barriers to entry in the methionine market[72] - The animal feed additive industry is expected to grow due to global trends such as meat industrialization, population growth, and sustainable development, with emerging markets shifting towards protein-rich diets[72] - In 2023, the company's operating performance improved due to increased production, stable prices, reduced raw material and energy costs, and profit protection measures, despite challenges in the macroeconomic environment[72] - Anhui's global market leadership in methionine was consolidated in 2023 due to successful marketing and completion of expansion and debottlenecking projects in Europe and China[73] - Anhui decided to stop exporting solid methionine from France to the US and redirect limited products to other regions and countries[73] - Anhui permanently closed a solid methionine production line in Europe and adjusted liquid methionine production to mitigate the impact of global demand slowdown in 2023[73] - Anhui's vitamin business profitability stabilized in 2023 despite significant price pressure, benefiting from prudent production and price management[74] - The company faces competition from large, well-funded companies and new entrants, with strategies including cost control, process improvements, and capacity expansion in China and Europe[112] - Risks related to product development and technological advancements, particularly in methionine production, could impact competitiveness if competitors achieve breakthroughs first[114] Risk Management - The Russia-Ukraine conflict and Red Sea ship attacks have increased uncertainty, potentially leading to supply disruptions and higher costs for raw materials and energy[107] - The company faces risks from global macroeconomic fluctuations, serving over 4,200 customers in more than 110 countries[111] - Key raw materials such as acrylic, sulfur, methanol, ammonia, and natural gas are sourced from a limited number of suppliers, with potential risks from price volatility and supply disruptions[113] - The company is exposed to currency exchange risks due to operations primarily in euros and dollars, while financial statements are consolidated in RMB[116] - Compliance risks include potential violations of anti-corruption, antitrust, and international sanctions regulations, with extensive employee training programs in place to mitigate these risks[108] - Environmental regulations and potential changes in emission standards could require additional investments in sustainability and environmental facilities[109] - Tax and tariff risks include potential increases in effective tax rates due to changes in local tax laws and geopolitical tensions affecting import regulations[118] - Industrial risks include potential damage to individuals, property, or the environment, with some facilities classified as "highest level" chemical bases under EU directives[119] - Production involves hazardous chemicals and complex processes, with risks of leaks, emissions, and waste exceeding standards, potentially leading to civil, criminal, and financial liabilities[120] - Disease outbreaks (e.g., avian flu, African swine fever) and production accidents could significantly impact livestock numbers, consumer demand, and the company's financial performance[121] - Mismanagement of production plans, equipment failures, or overestimation of market demand could harm customer relationships and future sales[122] - Increasing cybersecurity threats, including phishing, hacking, and malware, pose risks to IT systems and data, potentially causing operational disruptions and reputational damage

2023 年第三季度报告 单位：元 币种：人民币 证券代码：600299 证券简称：安迪苏 蓝星安迪苏股份有限公司 2023 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人郝志刚、主管会计工作负责人 Virginie Cayatte 及会计机构负责人（会计主管 人员）Virginie Cayatte 保证季度报告中财务信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 | --- | --- | --- | --- | --- | |------------------------------------------------|---------------|-----------------------------------------|--------------- ...

公司代码：600299 公司简称：安迪苏 2023 年半年度报告 蓝星安迪苏股份有限公司 2023 年半年度报告 1 / 165 2023 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人郝志刚、主管会计工作负责人 Virginie Cayatte 及会计机构负责人（会计主管 人员）Virginie Cayatte 声明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 本报告期内，本公司无利润分配预案或使用公积金转增股本预案。 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的未来计划、发展战略等前瞻性描述不构成公司对投资者的实质承诺，敬请 投资者注意投资风险。 七、 是否存在被控股股东及其他关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况？ 否 九、 是否存在半数以上董事无法保证公司 ...